Replicel Is On Fire Lately — Data In Feb.

[Hate da Bt]

We are all sad and pathetic.

We? All?
Delusion, convince yourself!

 

[Marcaronii]

We? All?
Delusion, convince yourself!

 

[Marcaronii]

I am sad and pathetic

We all are.. but @Hate da Bt Is trying to convince himself that he's not. Delusional!

 

[alibaba92]

We all are.. but @Hate da Bt Is trying to convince himself that he's not. Delusional!

we = those who cares about replicel / shiseido.

 

[ffar1989]

I hope Fevi will be released and do the job.

 

[luen12]

I wish that thread title would be true and we would actually get data in February. But I know it‘s just wishful thinking, very far away from reality.

 

[MeDK]

According to Replicel, they're only halfway with phase 2

RCH-01 is being co-developed by Shiseido Company and RepliCel in Asia and by RepliCel in the rest of the world. Under Shiseido's management, the product is anticipated to launch first in Japan while it continues to be developed elsewhere. RepliCel is planning a Phase 2 trial to answer important questions like: what is the best dose (number of cells) to see intended results and how many rounds of treatments are required to achieve intended results. Trial success will be measured by assessing changes in terminal and vellus hair density as well as cumulative hair thickness over a period at least one year.

There is some time still to go with the phase 2 trails.

 

[MeDK]

lol this release is outdated, thats why. they are doing a second trail here in Europe because they need to in order to be able to commercialize here as well. but their trail in japan is already finished and thats all they need to commercialize THERE. hence why "the product is anticipated to launch first in Japan WHILE it continues to be developed elsewhere"


trial 2 in japan is done and that should be enough if it was good enough.

But if you go through their press release from 15th october last year (2018)

Near-term catalysts to watch for over the next 15-18 months include:

• Anticipated announcement of clinical results from the Shiseido-funded pattern baldness study in Japan
• A decision from Shiseido on if and when it intends to launch of the RCH-01 in Japan

So its still at least one year period we're looking at. and if the 15-18 months is the time frame from that date. then we're talking end for 2019 for any kind of results.

 

[Marcaronii]

According to Replicel, they're only halfway with phase 2

RCH-01 is being co-developed by Shiseido Company and RepliCel in Asia and by RepliCel in the rest of the world. Under Shiseido's management, the product is anticipated to launch first in Japan while it continues to be developed elsewhere. RepliCel is planning a Phase 2 trial to answer important questions like: what is the best dose (number of cells) to see intended results and how many rounds of treatments are required to achieve intended results. Trial success will be measured by assessing changes in terminal and vellus hair density as well as cumulative hair thickness over a period at least one year.

There is some time still to go with the phase 2 trails.

Err ....we already know this. Lol.

 

[SuperDPAsteve]

@ everyone in this thread

*trial

 

[alibaba92]

View attachment 110370 I never post on here anymore but I follow this thread from time to time. For those that are worried about nothing being posted about the trial in 2018 this might relax some of your fears. This is from a hair loss discord back in July. Sorry about quality.

What make me wonder is that, Shiseido never said / shared anything to their business partner - Replicel, but to a random guy via email ?

 

[alibaba92]

The man he emailed is a professor from Tokyo Medical Unviersity, who Shiseido partnered with for the trial. As for Replicel, Shiseido and them have a very strained relationship because replicel did not honor some of the conditions for their licensing agreement.

Yah, I mean, the trial results and anything related to it is super sensitive and confidential and the professor should have known that and he should not disclose anything to a random guy on the internet.

Totally agree on the Replicel - Shiseido relationship.

 

[Joxy]

miR-195-5p Regulates Hair Follicle Inductivity of Dermal Papilla Cells by Suppressing Wnt/β-Catenin Activation

https://www.hindawi.com/journals/bmri/2018/4924356/

Is this similar to Replicel method?

 

[Hate da Bt]

miR-195-5p Regulates Hair Follicle Inductivity of Dermal Papilla Cells by Suppressing Wnt/β-Catenin Activation

https://www.hindawi.com/journals/bmri/2018/4924356/

Is this similar to Replicel method?

N O

 

[luen12]

Remember when we were all afraid, when we saw that the trial had the status „terminated“ on the english version of the Japanese clinical trials website? They now changed it from „terminated“ to „other“ and when you open it, the recruitment status is „complete: follow-up continuing“. That corresponds to the Japanese „recruitment completed - test ongoing“.

I know this isnt particularly great news, but at least it shows us that the trial wasn‘t terminated or aborted early, as some feared when people checked it in November.

 

[Milkonos]

Concerning stem cell researches in Japan. It appears that hairloss isn't the only thing that is being dealt with. There are also researches on Parkison and Alzheimer diseases, and also skin rejuvenation. Does anyone know where we can follow the progress of these researches ?
There are plenty of forums and threads about hairloss, but nothing (at least, that I could find) about skin rejuvenation

 

[Makaveli1988]

Still on fire lol

 

[SuperDPAsteve]

Concerning stem cell researches in Japan. It appears that hairloss isn't the only thing that is being dealt with. There are also researches on Parkison and Alzheimer diseases, and also skin rejuvenation. Does anyone know where we can follow the progress of these researches ?
There are plenty of forums and threads about hairloss, but nothing (at least, that I could find) about skin rejuvenation

Is your character loosely based on another character, Spiros?

 

[RolfLeeBuckler]

I have big news:
https://ceo.ca/@newswire/replicel-ceo-provides-2019-shareholder-update

With the clinical study of RCH-01 now successfully completed in Japan, RepliCel expects Shiseido to declare its near-term plans for RCH-01.

Secondary emphasis will be placed on the following initiatives:
-Clarifying Shiseido's plans for RCH-01 in Japan and Asia

RCH-01 – RepliCel's cell therapy for the treatment of Androgenic Alopecia has been the subject of a successful phase 1 trial in Europe and a clinical study now complete in Japan. Shiseido is expected to announce soon whether it will commercially launch the product in Japan or conduct further development and clinical testing. RepliCel will not plan for a phase 2 clinical trial of this product until it has the RCI-02 injector commercially available to use in such a trial and it has clarity from Shiseido regarding its plans for the product in Japan.

Partnership with Shiseido – The disagreement regarding the status of the agreement between Shiseido and RepliCel remains unresolved but is not the subject of any litigation or arbitration. RepliCel maintains the Agreement remains intact and is communicating with Shiseido regarding its expectation of a release of data from the recently completed study of RCH-01 in Japan and clarity around Shiseido's commercial plans for the product in Asia (the territory for the Shiseido license).

 

[Newlybalding]

I have big news:
https://ceo.ca/@newswire/replicel-ceo-provides-2019-shareholder-update

With the clinical study of RCH-01 now successfully completed in Japan, RepliCel expects Shiseido to declare its near-term plans for RCH-01.

Secondary emphasis will be placed on the following initiatives:
-Clarifying Shiseido's plans for RCH-01 in Japan and Asia

RCH-01 – RepliCel's cell therapy for the treatment of Androgenic Alopecia has been the subject of a successful phase 1 trial in Europe and a clinical study now complete in Japan. Shiseido is expected to announce soon whether it will commercially launch the product in Japan or conduct further development and clinical testing. RepliCel will not plan for a phase 2 clinical trial of this product until it has the RCI-02 injector commercially available to use in such a trial and it has clarity from Shiseido regarding its plans for the product in Japan.

Partnership with Shiseido – The disagreement regarding the status of the agreement between Shiseido and RepliCel remains unresolved but is not the subject of any litigation or arbitration. RepliCel maintains the Agreement remains intact and is communicating with Shiseido regarding its expectation of a release of data from the recently completed study of RCH-01 in Japan and clarity around Shiseido's commercial plans for the product in Asia (the territory for the Shiseido license).

ELI5 please, my brain is fried from work